293 related articles for article (PubMed ID: 32226347)
1. The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.
Wang A; Singh K; Ibrahim W; King B; Damsky W
Yale J Biol Med; 2020 Mar; 93(1):187-195. PubMed ID: 32226347
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Damsky W; Thakral D; McGeary MK; Leventhal J; Galan A; King B
J Am Acad Dermatol; 2020 Mar; 82(3):612-621. PubMed ID: 31185230
[TBL] [Abstract][Full Text] [Related]
3. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib.
Wang A; Rahman NT; McGeary MK; Murphy M; McHenry A; Peterson D; Bosenberg M; Flavell RA; King B; Damsky W
J Allergy Clin Immunol; 2021 May; 147(5):1795-1809. PubMed ID: 33317858
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors in dermatology: Part II. A comprehensive review.
Chapman S; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):414-422. PubMed ID: 34228996
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Multiorgan Sarcoidosis With Tofacitinib.
Damsky W; Young BD; Sloan B; Miller EJ; Obando JA; King B
ACR Open Rheumatol; 2020 Feb; 2(2):106-109. PubMed ID: 31916703
[TBL] [Abstract][Full Text] [Related]
7. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
8. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Granulomatosis: a Comprehensive Review.
Terziroli Beretta-Piccoli B; Mainetti C; Peeters MA; Laffitte E
Clin Rev Allergy Immunol; 2018 Feb; 54(1):131-146. PubMed ID: 29352388
[TBL] [Abstract][Full Text] [Related]
10. Use of Janus kinase inhibitors for granulomatous dermatoses: A systematic review.
Sood S; Heung M; Georgakopoulos JR; Mufti A; Prajapati VH; Yeung J
J Am Acad Dermatol; 2023 Aug; 89(2):357-359. PubMed ID: 36990321
[No Abstract] [Full Text] [Related]
11. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
12. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.
Cordes F; Lenker E; Weinhage T; Spille LJ; Bettenworth D; Varga G; Schmidt HH; Foell D
Inflamm Bowel Dis; 2021 May; 27(6):887-901. PubMed ID: 33165509
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for managing granuloma formation after dermal filler injection: three case reports and literature review.
Wang J; Chen Z; Wu L; Liao Y; Yu B
J Dermatolog Treat; 2024 Dec; 35(1):2338281. PubMed ID: 38632962
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
15. Lymphokines (MIF) in the serum of patients with sarcoidosis and cutaneous granuloma annulare.
Umbert P; Belcher RW; Winkelmann RK
Br J Dermatol; 1976 Nov; 95(5):481-5. PubMed ID: 791335
[TBL] [Abstract][Full Text] [Related]
16. Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report.
McPhie ML; Swales WC; Gooderham MJ
SAGE Open Med Case Rep; 2021; 9():2050313X211039477. PubMed ID: 34422275
[TBL] [Abstract][Full Text] [Related]
17. Bicarbonate enhances the inflammatory response by activating JAK/STAT signalling in LPS + IFN-γ-stimulated macrophages.
Kawakami T; Koike A; Maehara T; Hayashi T; Fujimori K
J Biochem; 2020 Jun; 167(6):623-631. PubMed ID: 31960927
[TBL] [Abstract][Full Text] [Related]
18. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
19. Defective neutrophil migration in granuloma annulare, necrobiosis lipoidica, and sarcoidosis.
Gange RW; Black MM; Carrington P
Arch Dermatol; 1979 Jan; 115(1):32-5. PubMed ID: 367286
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
Ma C; Jairath V; Vande Casteele N
Best Pract Res Clin Gastroenterol; 2019; 38-39():101606. PubMed ID: 31327403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
